GlassScriptPhysician profile
Yiwu Huang
NPI 1780798462
$219,911.39
in general payments reported to CMS, 2019-2025
49 companies · $41K in 2025
The $41K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $21K · 2021: $26K · 2022: $36K · 2023: $25K · 2024: $31K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Food and Beverage: $12K · Honoraria: $4,125 · Travel and Lodging: $3,078 · Consulting Fee: $2,370 · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,700.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,100.00 |
| Food and Beverage | $12,496.03 |
| Honoraria | $4,125.00 |
| Travel and Lodging | $3,078.12 |
| Consulting Fee | $2,370.00 |
| Education | $473.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $118,941.50 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Rigel Pharmaceuticals, INC. | $24,589.61 | 2019-2022 | |
| Exelixis INC. | $21,977.33 | 2019-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $17,602.78 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Eisai INC. | $6,823.28 | 2020-2025 | |
| Daiichi Sankyo INC. | $5,686.46 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,484.74 | 2019-2025 | |
| Coherus Oncology, INC. | $4,984.20 | 2022-2025 | Loqtorzi |
| Genentech USA, INC. | $2,976.54 | 2019-2025 | Tecentriq, Venclexta, Polivy |
| Jazz Pharmaceuticals INC. | $2,822.72 | 2020 | |
| Janssen Biotech, INC. | $1,227.84 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $829.38 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $711.08 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $625.62 | 2019-2025 | Opdivo |
| Beigene USA, INC. | $525.00 | 2021-2023 | Brukinsa |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $401.60 | 2022-2025 | Tivdak, Epkinly |
| Incyte Corporation | $371.27 | 2019-2025 | Monjuvi, Zynyz, Pemazyre |
| Astellas Pharma US INC | $362.57 | 2019-2025 | Vyloy |
| Lilly USA, LLC | $360.73 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $331.00 | 2019-2025 | |
| Celgene Corporation | $329.85 | 2019-2024 | Reblozyl |
| Taiho Oncology, INC. | $159.48 | 2019 | |
| Mirati Therapeutics, INC. | $146.00 | 2023 | Krazati |
| Genzyme Corporation | $140.15 | 2022-2024 | |
| Seagen INC. | $131.87 | 2022-2023 | Adcetris |
| Stemline Therapeutics INC. | $125.00 | 2025 | Orserdu |
| Pfizer INC. | $123.77 | 2019-2024 | |
| Amgen INC. | $99.75 | 2019 | |
| Sumitomo Pharma America, INC. | $91.71 | 2024 | Orgovyx |
| Puma Biotechnology, INC. | $87.95 | 2020-2025 | |
| Sobi, INC | $85.74 | 2022 | |
| Deciphera Pharmaceuticals INC. | $82.42 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Gilead Sciences, INC. | $81.17 | 2019-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $74.53 | 2025 | Ultomiris |
| Tersera Therapeutics LLC | $65.71 | 2019 | |
| Agios Pharmaceuticals, INC. | $56.99 | 2025 | Pyrukynd |
| Abbvie INC. | $47.59 | 2025 | |
| Emd Serono, INC. | $41.74 | 2019 | |
| Servier Pharmaceuticals LLC | $38.95 | 2025 | |
| Blueprint Medicines Corporation | $36.16 | 2024 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $33.13 | 2025 | Revuforj |
| Nuvation Bio INC. | $31.47 | 2025 | Ibtrozi |
| Karyopharm Therapeutics INC. | $29.94 | 2024 | Xpovio |
| Glaxosmithkline, LLC. | $29.16 | 2019 | |
| Myovant Sciences INC. | $23.09 | 2022 | |
| Adc Therapeutics America, INC. | $23.04 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.68 | 2025 | Danziten |
| Dendreon Pharmaceuticals LLC | $20.28 | 2024 | Provenge |
| Novocure INC. | $16.82 | 2023 | Optune |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiwu Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.